scispace - formally typeset
M

Martina Ulrich

Researcher at Charité

Publications -  82
Citations -  3498

Martina Ulrich is an academic researcher from Charité. The author has contributed to research in topics: Actinic keratosis & Skin cancer. The author has an hindex of 31, co-authored 81 publications receiving 3121 citations.

Papers
More filters
Journal ArticleDOI

Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study.

TL;DR: Evidence for the prevention of NMSC in immunocompromised patients is still missing and encouraging reports of protective effects of broad‐spectrum sunscreens in Immunocompetent patients are still missing.
Journal ArticleDOI

A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up.

TL;DR: Actinic keratoses frequently occur on sun‐exposed skin and are considered as in situ squamous cell carcinoma, but no treatment algorithm exists for first or second line therapies due to the lack of comparative studies.
Journal ArticleDOI

Dynamic Optical Coherence Tomography in Dermatology

TL;DR: Dynamic OCT (D-OCT) based on speckle variance OCT is of special interest as it allows the in vivo evaluation of blood vessels and their distribution within specific lesions, providing additional functional information and consequently greater density of data.
Journal ArticleDOI

Clinical applicability of in vivo reflectance confocal microscopy for the diagnosis of actinic keratoses.

TL;DR: RCM may be a promising technology for the noninvasive detection of AK and as adjunct tool to clinical diagnosis and monitoring, however, the preliminary nature of this study warrants further investigations.
Journal ArticleDOI

Reflectance Confocal Microscopy for Noninvasive Monitoring of Therapy and Detection of Subclinical Actinic Keratoses

TL;DR: The findings indicate that RCM allows noninvasive monitoring of treatment response in vivo and permits early detection of subclinical AK, thus substantiating the incentive for therapy.